Aridis Pharmaceuticals (NASDAQ:ARDS) Earns Hold Rating from Maxim Group

Maxim Group reiterated their hold rating on shares of Aridis Pharmaceuticals (NASDAQ:ARDSGet Rating) in a research note published on Tuesday morning, The Fly reports.

Aridis Pharmaceuticals Stock Performance

Aridis Pharmaceuticals stock opened at $1.86 on Tuesday. The stock’s 50 day moving average price is $1.54 and its 200 day moving average price is $1.55. The firm has a market capitalization of $32.93 million, a PE ratio of -0.50 and a beta of 1.13. Aridis Pharmaceuticals has a one year low of $0.88 and a one year high of $4.34.

Aridis Pharmaceuticals (NASDAQ:ARDSGet Rating) last announced its earnings results on Tuesday, August 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.39). On average, analysts forecast that Aridis Pharmaceuticals will post -0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aridis Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Commonwealth Equity Services LLC purchased a new position in shares of Aridis Pharmaceuticals in the fourth quarter worth approximately $47,000. Group One Trading L.P. purchased a new position in shares of Aridis Pharmaceuticals in the first quarter worth approximately $48,000. Minot Wealth Management LLC purchased a new position in shares of Aridis Pharmaceuticals in the first quarter worth approximately $88,000. Finally, Vanguard Group Inc. increased its position in shares of Aridis Pharmaceuticals by 3.3% in the first quarter. Vanguard Group Inc. now owns 524,122 shares of the company’s stock worth $922,000 after acquiring an additional 16,785 shares in the last quarter. Institutional investors and hedge funds own 7.46% of the company’s stock.

Aridis Pharmaceuticals Company Profile

(Get Rating)

Aridis Pharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

See Also

The Fly logo

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.